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BACKGROUND
Mental disorders have been increasingly
portrayed by the World Health Organiza-
tion (WHO) and health researchers as a
growing burden to global public health (1–
5). Just the sheer economic impact of men-
tal disorders is significant; it is expected to
cost almost a third of the projected US$47
trillion incurred by all non-communicable
diseases by 2030 (6). American and Euro-
pean research indicated in 2005 that 26–
27% of the adult population suffers from
a diagnosable mental disorder, represent-
ing over 57 million Americans and almost
83 million Europeans (7, 8). The Euro-
pean research was later revised in 2011
to 38% (approximately 160 million Euro-
peans) by including mental diagnoses usu-
ally not analyzed in these kinds of studies,
such as insomnia and alcoholism (9). In
Sweden as well as other countries, milder
mental symptoms are now being frequently
reported as common occurrences (10, 11),
especially among youth and the elderly (12,
13). These milder symptoms are increas-
ingly becoming highlighted as important;
research (for example, Swedish and Amer-
ican) have suggested that early mental
ill health can predict more severe men-
tal illness and mental disorders (such as
major depression) later in life (14–16) and
even premature death (17). It is, therefore,
often argued that early signs of mental ill
health need to be acknowledged and treated
to prevent the onset of mental disorders
(14–16, 18–21).
Depression is the most common of the
affective disorders,which are defined as dis-
orders of mood rather than disturbances
of thought or cognition (22). Depression
is estimated to have a point prevalence of
about 5% in the general population, and a
lifetime risk of about 15% (23). Globally,
more than 350 million people of all ages
are believed to suffer from depression (24).
Just in the European Union, a yearly preva-
lence of 6.9% of depression is estimated to
affect 30.3 million inhabitants (9).
Overall, the WHO now ranks depres-
sion as one of the most burdensome dis-
eases in the world, and the organization has
for some time projected and warned that
depression is predicted to be the highest-
ranking disease problem in the developed
world by 2020 (1, 2).
This description is, however, not with-
out controversy, and some scholars are
skeptical of how, for instance, depression
is viewed as an increasing widespread ill
health problem (25–29). The aim of this
article is to discuss some of these issues.
DISCUSSION
THE ANATOMY OF PUBLIC HEALTH
As Dubos argues in his classic book Mirage
of Health, the myths of Hygeia and Ascle-
pius symbolize the never-ending oscilla-
tion between two different points of view
in medicine: health as the natural order
of things and health as something to be
restored by correcting an imperfection
(30). The modern followers of Hygeia can
be understood as practitioners of public
health and the medical professionals as fol-
lowers of Asclepius (31). It is sometimes
argued that with the exception of the spe-
cialties of public health and family med-
icine, the focus of modern medicine is
mainly on the individual patient, rather
than relating their situation to their fami-
lies, communities, or the wider society (32).
However, while public health medicine has
long engaged in strategies of disease pre-
vention and health promotion, more indi-
vidualized practices of risk are argued to
have become a central dimension of the
politics of life in the twenty-first century
(33). Increasingly, we have come to regard
simply being at risk of future disease as
being a disease in its own right (28). Diag-
nostic labels now go beyond disease itself to
include risk factors for disease, sometimes
giving rise to a new source of social iden-
tity, namely a pre-disease (34). This is what
critics argue is underway with the intro-
duction of preconditions for major depres-
sion in DSM-5 (35). Focusing on precondi-
tions for disease may further increase what
the German sociologist, Ulrich Beck, has
called the “risk society” (36) and in a global
approach “world risk society” (37); a soci-
ety structured through individualization
where a social crisis appears as an individ-
ual crises, no longer perceived in terms of
their rootedness in the social realm. Think-
ing of depression in terms of risk is related
to the problematization of depressive ill-
ness in the population and as a public
health issue (38). But by trying to assess
potential risk factors for disease and dis-
orders at earlier stages, the concepts of
illness and risk may become increasingly
blurred (39).
THE GHOST IN THE MACHINE
A medical diagnosis is perhaps most readily
recognized as the official label that classi-
fies disease as a medically related problem,
and is the foundation from which sense-
making and experiences are crafted (34).
A diagnosis can validate a patient’s per-
ception of her symptoms by giving her
experience a name, and equally, it can
pathologize routine lived experience, such
as fluctuations in one’s mood (40). Medical
encounters usually take place within a sys-
tem where diagnostic handbooks and short
form tests are used as a fast way of judging a
person’s health status, a system that allows
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and encourages doctors to swiftly choose a
diagnosis without a comprehensive inves-
tigation of the whole situation surround-
ing the patient. As argued, for instance,
by psychiatrist David Healy, guidelines and
protocols are now part of an “industrializa-
tion of health care” as he calls it (41). This
is not the purpose for which these hand-
books were intended. The DSM was issued
as a manual for guiding decisions regard-
ing diagnosis, but has more often been used
as a steering document for diagnosis. For
instance, it is stated in the DSM-IV that,“It
is important that DSM-IV not to be applied
mechanically . . . and are not to be used
in a cookbook fashion” (p. xxxii) (42). By
using the DSM as a “fast track” to diagno-
sis, one may end up with a problem with
not just overdiagnosis, but also overtreat-
ment. In the medical encounter, the doctor
may judge it to be more dangerous not to
treat someone who may prove to be ill than
to treat them when actually there is no need
to do so, and as a precaution and in fear of
relapse recommend long-term use of med-
icines (43). Research has suggested that the
act of prescribing in itself might also sug-
gest a biological basis for a problem (44),
and that it appears that doctors are less
willing to consider non-drug treatments if
drug therapy is available, even when there
is no evidence that pharmacotherapy is
superior (45).
RISK OF OVERDIAGNOSIS AND
OVERTREATMENT
One pathway to overdiagnosis can be
through disease boundaries being widened
and treatment thresholds lowered to a
point where a medical label and subsequent
therapy may cause people more harm than
good (28). This broadening of diagnos-
tic criteria is argued to reflect medicaliza-
tion as much as discovery of previously
undetected sick people (35, 46–49). Non-
medical problems have become medical
ones with risking leading to overdiagno-
sis and overtreatment as the definition
of what constitutes an abnormality gets
increasingly broader (50).
Concern for the harm and costs of over-
diagnosis and overtreatment is now gain-
ing momentum, as the discussion of risk
assessment and suggestions of pre-disease
progress in the scientific debate (51, 52).
Missed, delayed, or incorrect diagnoses can
lead to inappropriate patient care, poor
patient outcomes, and increased costs (53).
In the United States, it has been estimated
that between $158 billion and $226 bil-
lion was wasted on overtreatment in 2011
(54), and that the cost of medicalization
in 2005 corresponded to almost 4% of
the total domestic expenditures on health
care that year, or $77 billion (55). Thus,
overdiagnosing depression “just in case” or
because of a risk assessment may take its toll
both health-wise and financially. One study
found overdiagnosis and overtreatment of
depression to be common in community
settings in the U.S. (56).
Whether the public benefits from taking
more and more medicines for increasingly
broadly defined disease is open to serious
question. Critics like Marcia Angell argues,
for instance, that one could make a strong
argument that Americans with minor ail-
ments suffer more from overmedication,
and all the side effects and drug interactions
that go with it, than from undermedica-
tion (48). Thus, overdiagnosing depression
“just in case” or because of a risk assess-
ment may take its toll both health-wise and
financially.
THE DEVIL IN THE DETAILS
Maybe, the devil is in the details. The “one
in four”figure for mental illness prevalence,
widely quoted as it is, has an unclear ori-
gin (57). Is it even reasonable that 27%
of the American and European population
is estimated to suffer from mental disor-
ders (or 38% Europeans depending on how
many disorders are included)? Or is that
approximately 8.5% of the Nordic popu-
lation prescribed as antidepressant med-
ication? (58). Or does it instead tell us
something about the contemporary global
community and our view of health and
ill health? Pharmaceutical companies have
for some time been accused of “disease
mongering” (28, 59), whereby a “new con-
dition” is promoted as a major public
health problem in order to create a mar-
ket for treatment, often without the pub-
lic’s knowledge, sometimes referred to as
the “public healthification” of social prob-
lems (60). And there is also the issue
of alleged financial ties not only between
the members of the DSM panels and the
pharmaceutical industry (61, 62) but also
between industry and doctors responsible
for clinical practical guidelines for other
medical conditions as well (63).
If normal events are misdiagnosed as
depression, this will risk leaving those who
are depressed untreated (extended waiting
lists to health care, wrong medications, or
lack of resources) and thereby create under-
treatment and overtreatment simultane-
ously. If depression is going to be viewed
as a growing public health problem, there
needs to be a distinction between ill health
problems that are medical problems and
those that are not.
SUMMARY
It is evident that there are conflicting views
regarding the officially proclaimed wide-
spread existence of mental disorders, and
depression in particular. On the one hand,
we face descriptions of a growing public
health burden and risk, but on the other
hand we have descriptions of overdiagno-
sis and overtreatment. Certainly, from a
public health perspective anyway, a med-
ical approach to mental disorders would
be troublesome, since increasing medical-
ization furthermore risks individualizing
mental problems that may have other
sources and thereby moves the focus away
from the social and political context of ill
health, for instance, poverty and inequality.
For the sake of public health, arguments
for increased diagnosis must therefore be
related to a possible danger of medicalizing
social problems and life crises. By includ-
ing people with mild problems in estimates
of mental illness, we risk losing support for
treating those people who have legitimate
disorders.
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